Unknown

Dataset Information

0

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.


ABSTRACT: Interstitial lung disease (ILD) is one of the most serious pulmonary complications of connective tissue diseases (CTDs) and it is characterized by a deep impact on morbidity and mortality. Due to the poor knowledge of CTD-ILD's natural history and due to the difficulties related to design of randomized control trials, there is a lack of prospective data about the prevalence, follow-up, and therapeutic efficacy. For these reasons, the choice of therapy for CTD-ILD is currently very challenging and still largely based on experts' opinion. Treatment is often based on steroids and conventional immunosuppressive drugs, but the recent publication of the encouraging results of the INBUILD trial has highlighted a possible effective and safe use of antifibrotic drugs as a new therapeutic option for these subjects. Aim of this review is to summarize the available data and recent advances about therapeutic strategies for ILD in the context of various CTD, such as systemic sclerosis, idiopathic inflammatory myopathy and Sjogren syndrome, systemic lupus erythematosus, mixed connective tissue disease and undifferentiated connective tissue disease, and interstitial pneumonia with autoimmune features, focusing also on ongoing clinical trials.

SUBMITTER: Vacchi C 

PROVIDER: S-EPMC7073957 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Vacchi Caterina C   Sebastiani Marco M   Cassone Giulia G   Cerri Stefania S   Della Casa Giovanni G   Salvarani Carlo C   Manfredi Andreina A  

Journal of clinical medicine 20200203 2


Interstitial lung disease (ILD) is one of the most serious pulmonary complications of connective tissue diseases (CTDs) and it is characterized by a deep impact on morbidity and mortality. Due to the poor knowledge of CTD-ILD's natural history and due to the difficulties related to design of randomized control trials, there is a lack of prospective data about the prevalence, follow-up, and therapeutic efficacy. For these reasons, the choice of therapy for CTD-ILD is currently very challenging an  ...[more]

Similar Datasets

| S-EPMC8126753 | biostudies-literature
| S-EPMC9308694 | biostudies-literature
| S-EPMC3032366 | biostudies-other
| S-EPMC7813437 | biostudies-literature
| S-EPMC7815631 | biostudies-literature
| S-EPMC8584507 | biostudies-literature
| S-EPMC3590889 | biostudies-other
| S-EPMC5493376 | biostudies-literature
| S-EPMC10729597 | biostudies-literature
2022-01-05 | GSE192985 | GEO